{
    "PMC5564609_3": [
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Delayed gastric emptying",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[15, 0.02]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Bleeding",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[6, 0.5]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Pancreatic fistula",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[39, 0.52]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Biliary fistula",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[2, 0.47]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Wound infection",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[5, 0.66]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Pulmonary complication",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[2, 0.1]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Skin orifice infection",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[1, 0.012]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Abdominal abscess",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[0, /]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Pancreatitis",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[2, 1]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Sepsis",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[1, 1]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Re-laparotomy",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[3, 0.6]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Mortality",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[0, /]"
        },
        {
            "subject": {
                "study type": "post-operative complications",
                "groups": "ERAS and Conventional",
                "parameter": "Readmission (in 30 days)",
                "test": "Fisher exact test",
                "ERAS group size": "76",
                "Conventional group size": "83"
            },
            "measures": "[incidences, P]",
            "outcomes": "[1, 1]"
        }
    ],
    "PMC5762325_3": [
        {
            "subject": {
                "analysis": "Correlation analysis",
                "cancer type": "pancreatic cancer",
                "clinical stage": "Not specified",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1",
                "expression type": "Low",
                "tumor tissue sample": "E-cadherin Low",
                "technique": "correlation analysis"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[-0.42, <0.001]"
        },
        {
            "subject": {
                "analysis": "Correlation analysis",
                "cancer type": "pancreatic cancer",
                "clinical stage": "Not specified",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1",
                "expression type": "High",
                "tumor tissue sample": "E-cadherin High",
                "technique": "correlation analysis"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[NaN, NaN]"
        },
        {
            "subject": {
                "study type": "In vitro",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1",
                "expression type": "Representative figures",
                "tissue type": "Pancreatic cancer",
                "stage": "I and IV"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[Figure 3A-3D, Representative figures]"
        },
        {
            "subject": {
                "study type": "In vitro",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1",
                "expression type": "Representative figures",
                "tissue type": "Pancreatic cancer",
                "stage": "I and IV"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[Figure 3, Representative figures]"
        },
        {
            "subject": {
                "correlation": "Inversely correlated",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[P < 0.001, Inversely correlated]"
        },
        {
            "subject": {
                "cancer stage": "Different clinical stage",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[Table 3, Correlation analysis]"
        },
        {
            "subject": {
                "protein expression": "STYK1 expression",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[P < 0.001, Inversely correlated]"
        },
        {
            "subject": {
                "protein expression": "E-cadherin expression",
                "protein 1": "E-cadherin",
                "protein 2": "STYK1"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[P < 0.001, Inversely correlated]"
        }
    ],
    "PMC3798558_3": [
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "CG",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465",
                "reference": "ref."
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "CA",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465",
                "odds ratio": "1.32",
                "confidence interval": "1.01-1.71"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.32, 0.042]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "CG",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465",
                "odds ratio": "1.00",
                "reference": "ref."
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "1 (C>T)",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "0.433",
                "controls": "0.442",
                "frequency": "0.439"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "2 (G>A)",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465",
                "odds ratio": "1.32",
                "confidence interval": "1.01-1.71",
                "P-value": "0.042"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "3 (T>G)",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "185",
                "controls": "1465",
                "odds ratio": "1.05",
                "confidence interval": "0.81-1.36",
                "P-value": "0.691"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis for XRCC1",
                "haplotype": "4 (T>A)",
                "gene": "XRCC1",
                "SNP 1": "rs1799782",
                "statistical method": "haplotype-effects logistic regression",
                "adjustment": "multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                "cases": "<0.001",
                "controls": "0.002",
                "frequency": "0.002"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC4423458_3": [
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                "accession": "70906435",
                "molecular weight": "56 kDa",
                "average SC cancer": "138.8",
                "average SC control": "52.1",
                "NSAF ratio": "2.2",
                "P-value (t-test)": "0.01481"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[2.2, 0.01481]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "C4b-binding protein alpha chain precursor",
                "accession": "4502503",
                "molecular weight": "67 kDa",
                "average SC cancer": "37.3",
                "average SC control": "11.5",
                "NSAF ratio": "2.3",
                "P-value (t-test)": "0.04311"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[2.3, 0.04311]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Serum albumin pre-pro-protein",
                "accession": "4502027",
                "molecular weight": "69 kDa",
                "average SC cancer": "986.0",
                "average SC control": "332.8",
                "NSAF ratio": "2.4",
                "P-value (t-test)": "0.00006"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[2.4, 0.00006]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Vitamin D-binding protein isoform 1 precursor",
                "accession": "32483410",
                "molecular weight": "53 kDa",
                "average SC cancer": "51.9",
                "average SC control": "19.2",
                "NSAF ratio": "2.4",
                "P-value (t-test)": "0.03919"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[2.4, 0.03919]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Kininogen-1 isoform 2 precursor",
                "accession": "4504893",
                "molecular weight": "48 kDa",
                "average SC cancer": "21.3",
                "average SC control": "5.5",
                "NSAF ratio": "3.8",
                "P-value (t-test)": "0.01109"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[3.8, 0.01109]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Alpha-2-macroglobulin precursor",
                "accession": "66932947",
                "molecular weight": "163 kDa",
                "average SC cancer": "127.9",
                "average SC control": "29.3",
                "NSAF ratio": "3.9",
                "P-value (t-test)": "0.00618"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[3.9, 0.00618]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Haptoglobin isoform 1 pre-pro-protein",
                "accession": "4826762",
                "molecular weight": "45 kDa",
                "average SC cancer": "83.8",
                "average SC control": "18.0",
                "NSAF ratio": "4.2",
                "P-value (t-test)": "0.00024"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[4.2, 0.00024]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                "accession": "70906439",
                "molecular weight": "52 kDa",
                "average SC cancer": "89.3",
                "average SC control": "17.3",
                "NSAF ratio": "4.3",
                "P-value (t-test)": "0.00133"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[4.3, 0.00133]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Complement C3 precursor",
                "accession": "115298678",
                "molecular weight": "187 kDa",
                "average SC cancer": "174.7",
                "average SC control": "35.6",
                "NSAF ratio": "4.3",
                "P-value (t-test)": "0.00612"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[4.3, 0.00612]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Myeloperoxidase precursor",
                "accession": "4557759",
                "molecular weight": "84 kDa",
                "average SC cancer": "70.2",
                "average SC control": "11.0",
                "NSAF ratio": "5.3",
                "P-value (t-test)": "0.02501"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[5.3, 0.02501]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Apolipoprotein A-I pre-pro-protein",
                "accession": "4557321",
                "molecular weight": "31 kDa",
                "average SC cancer": "29.8",
                "average SC control": "5.9",
                "NSAF ratio": "5.7",
                "P-value (t-test)": "0.02170"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[5.7, 0.02170]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                "accession": "4503689",
                "molecular weight": "95 kDa",
                "average SC cancer": "63.3",
                "average SC control": "9.3",
                "NSAF ratio": "6.4",
                "P-value (t-test)": "0.00031"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[6.4, 0.00031]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                "accession": "156523970",
                "molecular weight": "39 kDa",
                "average SC cancer": "7.3",
                "average SC control": "1.1",
                "NSAF ratio": "6.5",
                "P-value (t-test)": "0.00173"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[6.5, 0.00173]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Ceruloplasmin precursor",
                "accession": "4557485",
                "molecular weight": "122 kDa",
                "average SC cancer": "47.3",
                "average SC control": "5.6",
                "NSAF ratio": "7.5",
                "P-value (t-test)": "0.00114"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[7.5, 0.00114]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "PREDICTED: complement C4-A isoform 1",
                "accession": "341916194",
                "molecular weight": "193 kDa",
                "average SC cancer": "32.1",
                "average SC control": "4.5",
                "NSAF ratio": "7.7",
                "P-value (t-test)": "0.01791"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[7.7, 0.01791]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Alpha-1B-glycoprotein precursor",
                "accession": "21071030",
                "molecular weight": "54 kDa",
                "average SC cancer": "10.9",
                "average SC control": "1.2",
                "NSAF ratio": "8.3",
                "P-value (t-test)": "0.00468"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[8.3, 0.00468]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                "accession": "31542984",
                "molecular weight": "103 kDa",
                "average SC cancer": "5.5",
                "average SC control": "0.2",
                "NSAF ratio": "35.4",
                "P-value (t-test)": "0.00484"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[35.4, 0.00484]"
        },
        {
            "subject": {
                "analysis": "proteomic analysis",
                "protein identification criteria": "Table 1",
                "protein type": "more abundant in cancer",
                "disease": "pancreatic cancer",
                "control": "primary sclerosing cholangitis and benign strictures",
                "protein": "Apolipoprotein B-100 precursor",
                "accession": "105990532",
                "molecular weight": "516 kDa",
                "average SC cancer": "49.3",
                "average SC control": "1.0",
                "NSAF ratio": "55.7",
                "P-value (t-test)": "0.02595"
            },
            "measures": "[NSAF ratio, P-value (t-test)]",
            "outcomes": "[55.7, 0.02595]"
        }
    ],
    "PMC5589562_2": [
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-145-5p",
                "Accession no.": "MIMAT0000437",
                "Ratio": "8980.05"
            },
            "measures": "[Ratio]",
            "outcomes": "[8980.05]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-199a-5p",
                "Accession no.": "MIMAT0000231",
                "Ratio": "1563.68"
            },
            "measures": "[Ratio]",
            "outcomes": "[1563.68]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-199b-5p",
                "Accession no.": "MIMAT0000263",
                "Ratio": "296.31"
            },
            "measures": "[Ratio]",
            "outcomes": "[296.31]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-136-5p",
                "Accession no.": "MIMAT0000448",
                "Ratio": "228.24"
            },
            "measures": "[Ratio]",
            "outcomes": "[228.24]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-137",
                "Accession no.": "MIMAT0000429",
                "Ratio": "227.70"
            },
            "measures": "[Ratio]",
            "outcomes": "[227.70]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-139-5p",
                "Accession no.": "MIMAT0000250",
                "Ratio": "216.83"
            },
            "measures": "[Ratio]",
            "outcomes": "[216.83]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-127-3p",
                "Accession no.": "MIMAT0000446",
                "Ratio": "159.72"
            },
            "measures": "[Ratio]",
            "outcomes": "[159.72]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-337-5p",
                "Accession no.": "MIMAT0004695",
                "Ratio": "148.57"
            },
            "measures": "[Ratio]",
            "outcomes": "[148.57]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-139-3p",
                "Accession no.": "MIMAT0004552",
                "Ratio": "146.36"
            },
            "measures": "[Ratio]",
            "outcomes": "[146.36]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-487b",
                "Accession no.": "MIMAT0003180",
                "Ratio": "118.72"
            },
            "measures": "[Ratio]",
            "outcomes": "[118.72]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-199a-3p+hsa-miR-199b-3p",
                "Accession no.": "MIMAT0000232",
                "Ratio": "107.49"
            },
            "measures": "[Ratio]",
            "outcomes": "[107.49]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-1233",
                "Accession no.": "MIMAT0005588",
                "Ratio": "66.04"
            },
            "measures": "[Ratio]",
            "outcomes": "[66.04]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-379-5p",
                "Accession no.": "MIMAT0000733",
                "Ratio": "62.89"
            },
            "measures": "[Ratio]",
            "outcomes": "[62.89]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-660-5p",
                "Accession no.": "MIMAT0003338",
                "Ratio": "62.50"
            },
            "measures": "[Ratio]",
            "outcomes": "[62.50]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "TAS cells",
                "miRNA probe ID": "hsa-miR-335-5p",
                "Accession no.": "MIMAT0000765",
                "Ratio": "60.53"
            },
            "measures": "[Ratio]",
            "outcomes": "[60.53]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-205-5p",
                "Accession no.": "MIMAT0000266",
                "Ratio": "23077.19"
            },
            "measures": "[Ratio]",
            "outcomes": "[23077.19]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-200c-3p",
                "Accession no.": "MIMAT0000617",
                "Ratio": "5968.64"
            },
            "measures": "[Ratio]",
            "outcomes": "[5968.64]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-200b-3p",
                "Accession no.": "MIMAT0000318",
                "Ratio": "467.15"
            },
            "measures": "[Ratio]",
            "outcomes": "[467.15]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-429",
                "Accession no.": "MIMAT0001536",
                "Ratio": "171.07"
            },
            "measures": "[Ratio]",
            "outcomes": "[171.07]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-196b-5p",
                "Accession no.": "MIMAT0001080",
                "Ratio": "116.42"
            },
            "measures": "[Ratio]",
            "outcomes": "[116.42]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-582-5p",
                "Accession no.": "MIMAT0003247",
                "Ratio": "99.53"
            },
            "measures": "[Ratio]",
            "outcomes": "[99.53]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-135b-5p",
                "Accession no.": "MIMAT0000758",
                "Ratio": "87.82"
            },
            "measures": "[Ratio]",
            "outcomes": "[87.82]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-182-5p",
                "Accession no.": "MIMAT0000259",
                "Ratio": "55.81"
            },
            "measures": "[Ratio]",
            "outcomes": "[55.81]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-96-5p",
                "Accession no.": "MIMAT0000095",
                "Ratio": "53.82"
            },
            "measures": "[Ratio]",
            "outcomes": "[53.82]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-200a-3p",
                "Accession no.": "MIMAT0000682",
                "Ratio": "44.88"
            },
            "measures": "[Ratio]",
            "outcomes": "[44.88]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-4284",
                "Accession no.": "MIMAT0016915",
                "Ratio": "41.90"
            },
            "measures": "[Ratio]",
            "outcomes": "[41.90]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-345-5p",
                "Accession no.": "MIMAT0000772",
                "Ratio": "27.99"
            },
            "measures": "[Ratio]",
            "outcomes": "[27.99]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-378g",
                "Accession no.": "MIMAT0018937",
                "Ratio": "25.01"
            },
            "measures": "[Ratio]",
            "outcomes": "[25.01]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-203",
                "Accession no.": "MIMAT0000264",
                "Ratio": "22.43"
            },
            "measures": "[Ratio]",
            "outcomes": "[22.43]"
        },
        {
            "subject": {
                "study": "this study",
                "analysis": "miRNA expression analysis",
                "cell type": "PC cells",
                "miRNA probe ID": "hsa-miR-141-3p",
                "Accession no.": "MIMAT0000432",
                "Ratio": "21.69"
            },
            "measures": "[Ratio]",
            "outcomes": "[21.69]"
        }
    ],
    "PMC4190529_6": [
        {
            "subject": {
                "study type": "phase 3",
                "treatment": "gemcitabine",
                "control": "5-fluorouracil",
                "phase": "3",
                "median survival therapy": "5.7",
                "median survival control": "4.2",
                "one year survival therapy": "18%",
                "one year survival control": "2%",
                "side effects": "more favorable than 5-fluorouracil",
                "FDA approval": "1996.0"
            },
            "measures": "[median survival, one year survival]",
            "outcomes": "[5.7, 4.2, 18%, 2%]"
        },
        {
            "subject": {
                "study type": "phase 3",
                "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival therapy": "6.4",
                "median survival control": "6.0",
                "one year survival therapy": "24%",
                "one year survival control": "19%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2005.0"
            },
            "measures": "[median survival, one year survival]",
            "outcomes": "[6.4, 6.0, 24%, 19%]"
        },
        {
            "subject": {
                "study type": "phase 3",
                "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival therapy": "8.5",
                "median survival control": "6.7",
                "one year survival therapy": "35%",
                "one year survival control": "22%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2013.0"
            },
            "measures": "[median survival, one year survival]",
            "outcomes": "[8.5, 6.7, 35%, 22%]"
        },
        {
            "subject": {
                "study type": "phase 2/3",
                "treatment": "FOLFIRINOX *",
                "control": "gemcitabine",
                "phase": "2/3",
                "median survival therapy": "11.1",
                "median survival control": "6.8",
                "one year survival therapy": "48.4%",
                "one year survival control": "20.6%",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "n/a"
            },
            "measures": "[median survival, one year survival]",
            "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
        },
        {
            "subject": {
                "study type": "phase 2",
                "treatment": "cell encapsulation + ifosfamide",
                "control": "5-fluorouracil",
                "phase": "2",
                "median survival therapy": "10",
                "median survival control": "5",
                "one year survival therapy": "36%",
                "one year survival control": "18%",
                "side effects": "more favorable than 5-fluorouracil or gemcitabine #",
                "FDA approval": "n/a"
            },
            "measures": "[median survival, one year survival]",
            "outcomes": "[10, 5, 36%, 18%]"
        }
    ],
    "PMC5675623_3": [
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "ECOG performance status",
                "contrast": "> 0 vs. 0",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.47 (0.90, 2.41), 0.120]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Liver metastases",
                "contrast": "Yes vs. No",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.72 (1.01, 2.91), 0.045]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "No. of metastatic sites",
                "contrast": ">2 vs. <= 2",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.33 (0.9, 2.25), 0.28]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Prior radiation therapy",
                "contrast": "Yes vs. No",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.58 (0.95, 2.61), 0.077]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Prior FOLFIRINOX",
                "contrast": "Yes vs. No",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.73 (1.01, 2.98), 0.046]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                "contrast": "Yes vs. No",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.08 (0.58, 2.01), 0.80]"
        },
        {
            "subject": {
                "study": "A Cox proportional hazards model was used to assess the impact of multiple factors on OS from first phase I treatment",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Location of the tumor at presentation",
                "contrast": "body vs. head/neck",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[1.1 (0.6, 2.0), 0.64]"
        },
        {
            "subject": {
                "study": "A Cox proportional hazards model was used to assess the impact of multiple factors on OS from first phase I treatment",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Location of the tumor at presentation",
                "contrast": "tail vs. head/neck",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[0.6 (0.4, 1.1), 0.11]"
        },
        {
            "subject": {
                "study": "A Cox proportional hazards model was used to assess the impact of multiple factors on OS from first phase I treatment",
                "endpoint": "overall survival (OS)",
                "timeframe": "from first phase I treatment",
                "model": "Cox proportional hazards model",
                "variable": "Prior history of thromboembolic event",
                "contrast": "Yes vs. No",
                "statistical representation": "hazard ratio (95% CI)",
                "replicates": "not specified"
            },
            "measures": "[hazard ratio (95% CI), P value]",
            "outcomes": "[0.9 (0.5, 1.5), 0.63]"
        }
    ],
    "PMC4742219_3": [
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Age",
                "statistical representation": "HR (95% CI)",
                "unit": "year"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.874]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Gender",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "female vs. male"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.89 (0.60, 1.31), 0.544]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor size",
                "statistical representation": "HR (95% CI)",
                "unit": "-"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.13 (0.97, 1.33), 0.127]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor grade",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Grade II vs. I"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.00 (0.69, 1.45), 0.991]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Tumor grade",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Grade III vs. I"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.93 (0.27, 3.17), 0.906]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Lymph Nodes",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "yes vs. no"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.39 (0.81, 2.38), 0.229]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Margin",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "positive vs. negative"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.54 (1.06, 2.25), 0.025]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Vascular invasion",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "yes vs. no"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.99 (0.69, 1.42), 0.967]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Perineural invasion",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "yes vs. no"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[2.19 (0.87, 5.49), 0.097]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Time from surgery to first recurrence",
                "statistical representation": "HR (95% CI)",
                "unit": "year"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.883]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Lung + Other vs. Lung"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.25 (0.63, 2.48), 0.516]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Liver + Other vs. Lung"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.91 (1.10, 3.31), 0.022]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Peritoneal vs. Lung"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[6.32 (3.12, 12.79), < 0.001]"
        },
        {
            "subject": {
                "analysis": "Multivariable analysis for time from recurrence to death",
                "variable": "Recurrence pattern",
                "statistical representation": "HR (95% CI)",
                "unit": "-",
                "comparison": "Local vs. Lung"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[2.09 (1.10, 4.00), 0.025]"
        }
    ],
    "PMC4941379_3": [
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG-/CagA-",
                "chronic atrophic gastritis": "NaN",
                "sample size": "4555",
                "cases": "5",
                "crude incidence rate": "10.42",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[Ref, Ref]"
        },
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG+/CagA-",
                "chronic atrophic gastritis": "NaN",
                "sample size": "1984",
                "cases": "2",
                "crude incidence rate": "9.54",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[0.79, 0.15\u20134.08]"
        },
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG+/CagA+",
                "chronic atrophic gastritis": "NaN",
                "sample size": "2295",
                "cases": "14",
                "crude incidence rate": "58.13",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[5.05, 1.81\u201314.09]"
        },
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG-/CagA+",
                "chronic atrophic gastritis": "Present",
                "sample size": "205",
                "cases": "0",
                "crude incidence rate": "0",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[3.45, 1.38\u20138.64]"
        },
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG+/CagA+",
                "chronic atrophic gastritis": "Present",
                "sample size": "143",
                "cases": "1",
                "crude incidence rate": "64.61",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[5.50, 0.63\u201347.57]"
        },
        {
            "subject": {
                "study type": "incidence",
                "disease": "gastric cancer",
                "analysis type": "risk analysis",
                "H. pylori infection": "IgG+/CagA+",
                "chronic atrophic gastritis": "Present",
                "sample size": "315",
                "cases": "5",
                "crude incidence rate": "151.20",
                "reference": "Ref"
            },
            "measures": "[hazard ratio, confidence interval]",
            "outcomes": "[12.51, 3.57\u201343.22]"
        }
    ],
    "PMC3987090_5": [
        {
            "subject": {
                "study": "An X et al. 16",
                "year": "2010",
                "n": "89",
                "number of patients with NLR >5 (%)": "16 (17.9)",
                "overall survival (NLR >5 vs. \u22645) (months)": "2.4 versus 7.7",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 4.49",
                "P": "0.013"
            },
            "measures": "[hazard ratio, overall survival]",
            "outcomes": "[4.49, 2.4, 7.7]"
        },
        {
            "subject": {
                "study": "Wang DS et al. 17",
                "year": "2012",
                "n": "86",
                "number of patients with NLR >5 (%)": "12 (13.9)",
                "overall survival (NLR >5 vs. \u22645) (months)": "5.8 versus 10.2",
                "hazard ratio (NLR \u22645 was set at 1)": "NaN",
                "P": "NaN"
            },
            "measures": "[overall survival]",
            "outcomes": "[5.8, 10.2]"
        },
        {
            "subject": {
                "study": "Stotz M et al. 1, 7",
                "year": "2013",
                "n": "261",
                "number of patients with NLR >5 (%)": "79 (30.3)",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 2.53",
                "P": "< 0.01"
            },
            "measures": "[hazard ratio]",
            "outcomes": "[2.53]"
        },
        {
            "subject": {
                "study": "Our study",
                "year": "2013",
                "n": "253",
                "number of patients with NLR >5 (%)": "40 (15.8)",
                "overall survival (NLR >5 vs. \u22645) (months)": "6.0 versus 12.8",
                "hazard ratio (NLR \u22645 was set at 1)": "HR = 1.95",
                "P": "< 0.01"
            },
            "measures": "[hazard ratio, overall survival]",
            "outcomes": "[1.95, 6.0, 12.8]"
        },
        {
            "subject": {
                "proportion of patients with a pretreatment NLR of >5": "comparable across studies",
                "citations": "16, 17",
                "prognostic factor": "NLR",
                "therapy": "palliative chemotherapy",
                "outcome": "OS"
            },
            "measures": "[citations, prognostic factor, therapy, outcome]",
            "outcomes": "[16, 17, NLR, palliative chemotherapy, OS]"
        },
        {
            "subject": {
                "summary": "Summary of published studies reporting the association between NLR and the prognosis of APC patients receiving chemotherapy",
                "studies": "published",
                "association": "between NLR and prognosis",
                "patients": "APC",
                "therapy": "chemotherapy"
            },
            "measures": "[studies, association, patients, therapy]",
            "outcomes": "[published, NLR, prognosis, APC, chemotherapy]"
        },
        {
            "subject": {
                "footnote": "NA, not available",
                "study": "Stotz M et al. 1, 7",
                "data": "pooled",
                "patients": "261",
                "therapy": "chemotherapy and no chemotherapy"
            },
            "measures": "[study, data, patients, therapy]",
            "outcomes": "[Stotz M et al. 1, 7, 261, chemotherapy and no chemotherapy]"
        }
    ],
    "PMC4728116_3": [
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Family history of pancreatic cancer",
                "cases": "11",
                "controls": "3",
                "crude OR": "3.67",
                "crude 95% CI": "1.02-13.14",
                "adjusted OR1": "4.04",
                "adjusted 1 95% CI": "1.08-15.07",
                "adjusted OR2": "1.23",
                "adjusted 2 95% CI": "1.11-3.70"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.23, 1.11-3.70]"
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "BMI",
                "category": "<24.0",
                "cases": "197",
                "controls": "230",
                "crude OR": "1.00",
                "crude 95% CI": "reference",
                "adjusted OR1": "1.78",
                "adjusted 1 95% CI": "1.22-2.58",
                "adjusted OR2": "1.77",
                "adjusted 2 95% CI": "1.22-2.57"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.77, 1.22-2.57]"
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Diabetes",
                "cases": "49",
                "controls": "26",
                "crude OR": "2.69",
                "crude 95% CI": "1.51-4.77",
                "adjusted OR1": "2.60",
                "adjusted 1 95% CI": "1.41-4.79",
                "adjusted OR2": "2.96",
                "adjusted 2 95% CI": "1.48-5.92"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[2.96, 1.48-5.92]"
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Cholecystitis",
                "cases": "17",
                "controls": "10",
                "crude OR": "1.89",
                "crude 95% CI": "0.84-4.24",
                "adjusted OR1": "1.91",
                "adjusted 1 95% CI": "0.83-4.38",
                "adjusted OR2": "1.35",
                "adjusted 2 95% CI": "0.50-3.68"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.35, 0.50-3.68]"
        },
        {
            "subject": {
                "analysis": "Characteristics of patients associated with risk of pancreatic cancer",
                "characteristic": "Gallstone",
                "cases": "14",
                "controls": "5",
                "crude OR": "2.80",
                "crude 95% CI": "1.01-7.77",
                "adjusted OR1": "2.58",
                "adjusted 1 95% CI": "0.89-7.44",
                "adjusted OR2": "2.68",
                "adjusted 2 95% CI": "0.65-11.07"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[2.68, 0.65-11.07]"
        },
        {
            "subject": {
                "analysis": "Risk factors for pancreatic cancer",
                "factor": "Smoking",
                "cases": "-",
                "controls": "-",
                "crude OR": "1.78",
                "crude 95% CI": "1.02-3.10",
                "adjusted OR1": "-",
                "adjusted 1 95% CI": "-",
                "adjusted OR2": "-",
                "adjusted 2 95% CI": "-"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.78, 1.02-3.10]"
        },
        {
            "subject": {
                "analysis": "Risk factors for pancreatic cancer",
                "factor": "Family history of pancreatic cancer",
                "cases": "-",
                "controls": "-",
                "crude OR": "1.23",
                "crude 95% CI": "1.11-3.70",
                "adjusted OR1": "-",
                "adjusted 1 95% CI": "-",
                "adjusted OR2": "-",
                "adjusted 2 95% CI": "-"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.23, 1.11-3.70]"
        },
        {
            "subject": {
                "analysis": "Risk factors for pancreatic cancer",
                "factor": "High body mass index",
                "cases": "-",
                "controls": "-",
                "crude OR": "1.77",
                "crude 95% CI": "1.22-2.57",
                "adjusted OR1": "-",
                "adjusted 1 95% CI": "-",
                "adjusted OR2": "-",
                "adjusted 2 95% CI": "-"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[1.77, 1.22-2.57]"
        },
        {
            "subject": {
                "analysis": "Risk factors for pancreatic cancer",
                "factor": "Diabetes",
                "cases": "-",
                "controls": "-",
                "crude OR": "2.96",
                "crude 95% CI": "1.48-5.92",
                "adjusted OR1": "-",
                "adjusted 1 95% CI": "-",
                "adjusted OR2": "-",
                "adjusted 2 95% CI": "-"
            },
            "measures": "[adjusted OR, 95% CI]",
            "outcomes": "[2.96, 1.48-5.92]"
        }
    ],
    "PMC4741511_2": [
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib",
                "LDH serum levels": "\u2264 UNR",
                "patients number": "31",
                "patients percentage": "44%"
            },
            "measures": "[PFS, OS]",
            "outcomes": "[7.6, 12.7]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib",
                "LDH serum levels": "> UNR",
                "patients number": "6",
                "patients percentage": "8%"
            },
            "measures": "[PFS, OS]",
            "outcomes": "[2.8, 5.9]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy alone",
                "LDH serum levels": "\u2264 UNR",
                "patients number": "27",
                "patients percentage": "38%"
            },
            "measures": "[PFS, OS]",
            "outcomes": "[3.3, 8.6]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy alone",
                "LDH serum levels": "> UNR",
                "patients number": "7",
                "patients percentage": "10%"
            },
            "measures": "[PFS, OS]",
            "outcomes": "[2.2, 5.2]"
        },
        {
            "subject": {
                "p-value": "0.0012",
                "metric": "PFS",
                "outcome": "2.2"
            }
        },
        {
            "subject": {
                "metric": "OS",
                "outcome": "5.2"
            }
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "metric": "p",
                "outcome": "0.0012"
            }
        }
    ],
    "PMC5522086_3": [
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "TP53",
                "activation z-score": "-2.353",
                "P-value of overlap": "3.34\u00d710\u221232"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-2.353, 3.34\u00d710\u221232]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "NUPR1",
                "log ratio": "-2.52",
                "activation z-score": "-3.977",
                "P-value of overlap": "4.62\u00d710\u221213"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[-2.52, -3.977, 4.62\u00d710\u221213]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "NKX2-3",
                "activation z-score": "-3.455",
                "P-value of overlap": "5.88\u00d710\u221212"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-3.455, 5.88\u00d710\u221212]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "HNF1A",
                "activation z-score": "-2.359",
                "P-value of overlap": "8.82\u00d710\u221212"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-2.359, 8.82\u00d710\u221212]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "CDKN2A",
                "log ratio": "1.737",
                "activation z-score": "-3.219",
                "P-value of overlap": "1.34\u00d710\u221211"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[1.737, -3.219, 1.34\u00d710\u221211]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "estrogen receptor",
                "activation z-score": "-2.299",
                "P-value of overlap": "9.57\u00d710\u221210"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-2.299, 9.57\u00d710\u221210]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "RB1",
                "activation z-score": "-4.286",
                "P-value of overlap": "3.74\u00d710\u22128"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-4.286, 3.74\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "TCF3",
                "activation z-score": "-3.116",
                "P-value of overlap": "4.32\u00d710\u22128"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-3.116, 4.32\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "TRIM24",
                "activation z-score": "-3.714",
                "P-value of overlap": "6.26\u00d710\u22127"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-3.714, 6.26\u00d710\u22127]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "BCL6",
                "activation z-score": "-2.313",
                "P-value of overlap": "1.60\u00d710\u22126"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-2.313, 1.60\u00d710\u22126]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "NR5A2",
                "log ratio": "-2.876",
                "activation z-score": "-2.7",
                "P-value of overlap": "7.26\u00d710\u22126"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[-2.876, -2.7, 7.26\u00d710\u22126]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "SATB1",
                "log ratio": "-0.814",
                "activation z-score": "-2.003",
                "P-value of overlap": "1.09\u00d710\u22125"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[-0.814, -2.003, 1.09\u00d710\u22125]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "IRF4",
                "log ratio": "2.115",
                "activation z-score": "-2.41",
                "P-value of overlap": "4.24\u00d710\u22125"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[2.115, -2.41, 4.24\u00d710\u22125]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "RBL1",
                "activation z-score": "-3.124",
                "P-value of overlap": "1.72\u00d710\u22124"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-3.124, 1.72\u00d710\u22124]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "inhibited upstream transcriptors",
                "upstream regulator": "SPDEF",
                "activation z-score": "-2.887",
                "P-value of overlap": "2.39\u00d710\u22124"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[-2.887, 2.39\u00d710\u22124]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "STAT3",
                "activation z-score": "2.924",
                "P-value of overlap": "5.78\u00d710\u221219"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[2.924, 5.78\u00d710\u221219]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "CTNNB1",
                "activation z-score": "3.359",
                "P-value of overlap": "1.99\u00d710\u221215"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[3.359, 1.99\u00d710\u221215]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "SP1",
                "activation z-score": "2.06",
                "P-value of overlap": "4.79\u00d710\u221213"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[2.06, 4.79\u00d710\u221213]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "CEBPB",
                "activation z-score": "2.866",
                "P-value of overlap": "2.62\u00d710\u221212"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[2.866, 2.62\u00d710\u221212]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "NFkB (complex)",
                "activation z-score": "6.314",
                "P-value of overlap": "1.43\u00d710\u221211"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[6.314, 1.43\u00d710\u221211]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "TBX2",
                "activation z-score": "4.99",
                "P-value of overlap": "1.62\u00d710\u221211"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[4.99, 1.62\u00d710\u221211]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "IRF1",
                "activation z-score": "3.759",
                "P-value of overlap": "2.76\u00d710\u221211"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[3.759, 2.76\u00d710\u221211]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "IRF7",
                "log ratio": "1.504",
                "activation z-score": "5.591",
                "P-value of overlap": "2.88\u00d710\u221210"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[1.504, 5.591, 2.88\u00d710\u221210]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "FOXM1",
                "log ratio": "2.152",
                "activation z-score": "4.395",
                "P-value of overlap": "5.12\u00d710\u221210"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[2.152, 4.395, 5.12\u00d710\u221210]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "STAT1",
                "activation z-score": "4.576",
                "P-value of overlap": "2.05\u00d710\u22128"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[4.576, 2.05\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "ETS1",
                "log ratio": "0.863",
                "activation z-score": "2.575",
                "P-value of overlap": "5.06\u00d710\u22128"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[0.863, 2.575, 5.06\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "JUN",
                "activation z-score": "2.045",
                "P-value of overlap": "5.57\u00d710\u22128"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[2.045, 5.57\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "FOXO1",
                "activation z-score": "3.242",
                "P-value of overlap": "9.35\u00d710\u22128"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[3.242, 9.35\u00d710\u22128]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "E2F3",
                "log ratio": "1.137",
                "activation z-score": "2.394",
                "P-value of overlap": "1.16\u00d710\u22126"
            },
            "measures": "[log ratio, activation z-score, P-value of overlap]",
            "outcomes": "[1.137, 2.394, 1.16\u00d710\u22126]"
        },
        {
            "subject": {
                "table": "Table 3",
                "analysis": "IPA",
                "category": "activation upstream transcriptors",
                "upstream regulator": "MBD2",
                "activation z-score": "2.549",
                "P-value of overlap": "5.41\u00d710\u22126"
            },
            "measures": "[activation z-score, P-value of overlap]",
            "outcomes": "[2.549, 5.41\u00d710\u22126]"
        }
    ],
    "PMC4941331_3": [
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "tissue sample": "Tumor tissue sample",
                "cytoplasmic CDH1 expression": "Low",
                "nuclear HDAC3 expression": "Low",
                "statistical method": "Spearman correlation coefficient",
                "correlation coefficient": "-0.348",
                "P-value": "0.001"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[-0.348, 0.001]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "tissue sample": "Tumor tissue sample",
                "cytoplasmic CDH1 expression": "High",
                "nuclear HDAC3 expression": "High",
                "statistical method": "Spearman correlation coefficient",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[0.440, < 0.001]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "tissue sample": "Tumor tissue sample",
                "cytoplasmic CDH1 expression": "Low",
                "nuclear HDAC3 expression": "High",
                "statistical method": "Spearman correlation coefficient",
                "correlation coefficient": "-0.348",
                "P-value": "0.001"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[-0.348, 0.001]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "tissue sample": "Tumor tissue sample",
                "cytoplasmic CDH1 expression": "High",
                "nuclear HDAC3 expression": "Low",
                "statistical method": "Spearman correlation coefficient",
                "correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[correlation coefficient, P-value]",
            "outcomes": "[0.440, < 0.001]"
        },
        {
            "subject": {
                "analysis": "No correlations were found between cytoplasmic HDAC3 expression and CDH1 expression location",
                "tissue sample": "Tumor tissue sample",
                "statistical method": "Spearman correlation coefficient",
                "P-value": "> 0.05"
            },
            "measures": "[statistical method, P-value]",
            "outcomes": "[Spearman correlation coefficient, > 0.05]"
        }
    ],
    "PMC6062623_3": [
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density (k)": "0.1",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.76, 0.002]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density (k)": "0.15",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.15, 0.008]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density (k)": "0.2",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.25, 0.006]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density (k)": "0.25",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.08, 0.009]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density (k)": "0.1",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-1.04, 0.32]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density (k)": "0.15",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-2.58, 0.022]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density (k)": "0.2",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.36, 0.005]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density (k)": "0.25",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.04, 0.01]"
        },
        {
            "subject": {
                "prediction": "Increased local efficiency",
                "confidence": "High",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-6.76, 0.001]"
        },
        {
            "subject": {
                "prediction": "Increased local efficiency",
                "confidence": "High",
                "statistical test": "t-test",
                "statistical representation": "t-statistic and p-value"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-4.21, 0.001]"
        }
    ],
    "PMC5464866_2": [
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "cancerous tissues",
                "FXR expression": "strong positive",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "adjacent tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression, Number of positive cases, Number of negative cases]",
            "outcomes": "[88, 54 (61.4%), 34 (38.6%)]"
        },
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "adjacent tissues",
                "FXR expression": "30.7% positive",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "cancerous tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "paired normal tissues",
                "FXR expression": "different levels",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "cancerous tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "cancerous tissues",
                "FXR expression": "negative to strong positive",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "paired normal tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "paired normal tissues",
                "FXR expression": "ranging from negative to strong positive",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "cancerous tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "immunohistochemistry",
                "tissue type": "cancerous tissues",
                "FXR expression": "significant difference",
                "study goal": "confirm the role of FXR in pancreatic cancer",
                "comparison to": "paired normal tissues",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression]",
            "outcomes": "[]"
        }
    ],
    "PMC5687650_6": [
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Gender",
                "category": "Women or Men",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[0.770 (0.528-1.124), 0.175]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Age",
                "category": ">65 years or \u226465years",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[0.773 (0.537-1.110), 0.163]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "PLR",
                "category": "high or low",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[0.922 (0.641-1.325), 0.660]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "NLR",
                "category": "high or low",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[1.007 (0.701-1.448), 0.969]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy PLR ratio",
                "category": ">1 or \u22641",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[1.272 (0.881-1.837), 0.199]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy NLR ratio",
                "category": ">1 or \u22641",
                "statistical representation": "OR (95% CI)",
                "replicates": "-",
                "outcome": "OS"
            },
            "measures": "[OR (95% CI), P value]",
            "outcomes": "[1.902 (1.290-2.803), 0.001**]"
        },
        {
            "subject": {
                "method": "By using the post-/pre-chemotherapy PLR or NLR ratios, patients were separated into two groups respectively",
                "criterion": "post-/pre-chemotherapy ratios <1 or \u22651",
                "outcome": "OS"
            },
            "measures": "[metric, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "finding": "changes in NLR level, but not PLR level, after chemotherapy predicted outcomes",
                "metric": "-",
                "outcome": "OS"
            },
            "measures": "[metric, -]",
            "outcomes": "[outcome, -]"
        }
    ],
    "PMC5641200_3": [
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "5",
                "adverse event": "Red blood cells count decreased",
                "grade": "G1",
                "percentage": "83"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[5, 83]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Red blood cells count decreased",
                "grade": "G2",
                "percentage": "17"
            },
            "measures": "[grade 2, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "Leukopenia",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Leukopenia",
                "grade": "G2",
                "percentage": "17"
            },
            "measures": "[grade 2, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "4",
                "adverse event": "Neutropenia",
                "grade": "G1",
                "percentage": "67"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[4, 67]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "AST increase",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "4",
                "adverse event": "ALT increase",
                "grade": "G1",
                "percentage": "67"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[4, 67]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "GGT increase",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Hypocalcemia",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Hyponatremia",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "Nausea",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "2",
                "adverse event": "Vomiting",
                "grade": "G1",
                "percentage": "33"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[2, 33]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "-",
                "adverse event": "Diarrhea",
                "grade": "G1",
                "percentage": "-"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Abdominal pain",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "Oral mucositis",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "2",
                "adverse event": "Dyspepsia",
                "grade": "G1",
                "percentage": "33"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[2, 33]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Dysgeusia",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "Anorexia",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "1",
                "adverse event": "Alopecia",
                "grade": "G1",
                "percentage": "17"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 17]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 1",
                "number of patients": "3",
                "adverse event": "Fatigue",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "2",
                "adverse event": "Red blood cells count decreased",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[2, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "-",
                "adverse event": "Red blood cells count decreased",
                "grade": "G2",
                "percentage": "-"
            },
            "measures": "[grade 2, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "2",
                "adverse event": "Leukopenia",
                "grade": "G1",
                "percentage": "50"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[2, 50]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "1",
                "adverse event": "Leukopenia",
                "grade": "G2",
                "percentage": "25"
            },
            "measures": "[grade 2, number of patients]",
            "outcomes": "[1, 25]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "1",
                "adverse event": "Neutropenia",
                "grade": "G1",
                "percentage": "25"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 25]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "1",
                "adverse event": "Neutropenia",
                "grade": "G2",
                "percentage": "25"
            },
            "measures": "[grade 2, number of patients]",
            "outcomes": "[1, 25]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "4",
                "adverse event": "AST increase",
                "grade": "G1",
                "percentage": "100"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[4, 100]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "3",
                "adverse event": "ALT increase",
                "grade": "G1",
                "percentage": "75"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[3, 75]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "-",
                "adverse event": "GGT increase",
                "grade": "G1",
                "percentage": "-"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "1",
                "adverse event": "Hypocalcemia",
                "grade": "G1",
                "percentage": "25"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 25]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "-",
                "adverse event": "Hyponatremia",
                "grade": "G1",
                "percentage": "-"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "-",
                "adverse event": "Nausea",
                "grade": "G1",
                "percentage": "-"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "-",
                "adverse event": "Vomiting",
                "grade": "G1",
                "percentage": "-"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[-, -]"
        },
        {
            "subject": {
                "study": "treatment related adverse events",
                "analysis": "adverse events by dose level",
                "dose level": "Level 2",
                "number of patients": "1",
                "adverse event": "Diarrhea",
                "grade": "G1",
                "percentage": "25"
            },
            "measures": "[grade 1, number of patients]",
            "outcomes": "[1, 25]"
        }
    ],
    "PMC5716794_2": [
        {
            "subject": {
                "differential diagnosis": "mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC)",
                "challenge": "clinical significance",
                "imaging presentation": "similarity"
            },
            "measures": "[disease, MFCP, PDAC]",
            "outcomes": "[clinical significance, challenge]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "55",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.687 \u00b1 0.079, 89.1, 50.0, 86.4, 56.3, 80.5]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "82",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.694 \u00b1 0.077, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "99",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.707 \u00b1 0.074, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "134",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.731 \u00b1 0.070, 90.6, 50.0, 86.6, 59.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "152",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.751 \u00b1 0.067, 89.1, 55.6, 87.7, 58.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "161",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.756 \u00b1 0.065, 89.1, 55.6, 87.7, 58.9, 81.7]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "189",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.770 \u00b1 0.062, 90.6, 55.6, 87.9, 62.5, 82.9]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "214",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.788 \u00b1 0.059, 92.2, 55.6, 88.1, 66.7, 84.2]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "223",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.793 \u00b1 0.058, 93.8, 55.6, 88.3, 71.6, 85.4]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "imaging modality": "diffusion-weighted imaging (DWI)",
                "disease": "healthy pancreas",
                "ROI size (mm2)": "245",
                "technique": "quantitative measurement of apparent diffusion coefficient (ADC) values",
                "statistical representation": "mean +- SE (95% CI)"
            },
            "measures": "[AUC, sensitivity, specificity, PPV, NPV, ACC]",
            "outcomes": "[0.800 \u00b1 0.056, 95.3, 55.6, 88.4, 76.9, 86.6]"
        }
    ],
    "PMC3757392_2": [
        {
            "subject": {
                "vector": "C595:MUC1",
                "cell line": "Capan-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "++",
                "Flow": "40",
                "Confocal": "++",
                "Do": "170"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[++, 40, ++, 170]"
        },
        {
            "subject": {
                "vector": "",
                "cell line": "Cfpac-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "+++",
                "Flow": "500",
                "Confocal": "+++",
                "Do": "140"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[+++, 500, +++, 140]"
        },
        {
            "subject": {
                "vector": "",
                "cell line": "Panc-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "+++",
                "Flow": "80",
                "Confocal": "+++",
                "Do": "160"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[+++, 80, +++, 160]"
        },
        {
            "subject": {
                "vector": "394:uPA",
                "cell line": "Capan-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "++",
                "Flow": "88",
                "Confocal": "++",
                "Do": "190"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[++, 88, ++, 190]"
        },
        {
            "subject": {
                "vector": "",
                "cell line": "Cfpac-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "+++",
                "Flow": "92",
                "Confocal": "+++",
                "Do": "130"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[+++, 92, +++, 130]"
        },
        {
            "subject": {
                "vector": "",
                "cell line": "Panc-1",
                "analysis": "Comparison of cell line properties",
                "ICC": "+++",
                "Flow": "91",
                "Confocal": "+++",
                "Do": "170"
            },
            "measures": "[ICC, Flow, Confocal, Do]",
            "outcomes": "[+++, 91, +++, 170]"
        },
        {
            "subject": {
                "MUC1": "",
                "immunoreactivity": "strong",
                "expression": "cell membrane",
                "analysis": "Comparison of cell line properties",
                "method": "confocal microscopy",
                "outcome": "green image"
            },
            "measures": "[immunoreactivity, expression, analysis, method, outcome]",
            "outcomes": "[strong, cell membrane, Comparison of cell line properties, confocal microscopy, green image]"
        },
        {
            "subject": {
                "MUC1": "",
                "immunoreactivity": "strong",
                "expression": "cell membrane",
                "analysis": "Comparison of cell line properties",
                "method": "flow cytometry",
                "outcome": "purple peak"
            },
            "measures": "[immunoreactivity, expression, analysis, method, outcome]",
            "outcomes": "[strong, cell membrane, Comparison of cell line properties, flow cytometry, purple peak]"
        },
        {
            "subject": {
                "MUC1": "",
                "immunoreactivity": "strong",
                "expression": "cell membrane",
                "analysis": "Comparison of cell line properties",
                "method": "cell survival",
                "outcome": "incubation in AC"
            },
            "measures": "[immunoreactivity, expression, analysis, method, outcome]",
            "outcomes": "[strong, cell membrane, Comparison of cell line properties, cell survival, incubation in AC]"
        },
        {
            "subject": {
                "C595": "",
                "immunoreactivity": "strong",
                "expression": "cell membrane",
                "analysis": "Comparison of cell line properties",
                "method": "immunocytochemistry",
                "outcome": "brown stain"
            },
            "measures": "[immunoreactivity, expression, analysis, method, outcome]",
            "outcomes": "[strong, cell membrane, Comparison of cell line properties, immunocytochemistry, brown stain]"
        },
        {
            "subject": {
                "A2": "",
                "immunoreactivity": "not found",
                "expression": "cell membrane",
                "analysis": "Comparison of cell line properties",
                "method": "immunocytochemistry",
                "outcome": ""
            },
            "measures": "[immunoreactivity, expression, analysis, method, outcome]",
            "outcomes": "[not found, cell membrane, Comparison of cell line properties, immunocytochemistry, ]"
        }
    ]
}